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Endothelial dysfunction is a central hallmark of dia-
betes. The transcriptional coactivator PGC-1a is a
powerful regulator of metabolism, but its role in
endothelial cells remains poorly understood. We
show here that endothelial PGC-1a expression is
high in diabetic rodents and humans and that PGC-
1a powerfully blocks endothelial migration in cell
culture and vasculogenesis in vivo. Mechanistically,
PGC-1a induces Notch signaling, blunts activation
of Rac/Akt/eNOS signaling, and renders endothelial
cells unresponsive to established angiogenic fac-
tors. Transgenic overexpression of PGC-1a in the
endothelium mimics multiple diabetic phenotypes,
including aberrant re-endothelialization after carotid
injury, blunted wound healing, and reduced blood
flow recovery after hindlimb ischemia. Conversely,
deletion of endothelial PGC-1a rescues the blunted
wound healing and recovery from hindlimb ischemia
seen in type 1 and type 2 diabetes. Endothelial PGC-
1a thus potently inhibits endothelial function and
angiogenesis, and induction of endothelial PGC-1a
contributes to multiple aspects of vascular dysfunc-
tion in diabetes.246 Cell Metabolism 19, 246–258, February 4, 2014 ª2014 Elsevier InINTRODUCTION
Vascular endothelial dysfunction predisposes diabetic patients
to numerous cardiovascular complications, including critical
limb ischemia, the leading cause of limb amputation worldwide
(Hamilton et al., 2007; Rask-Madsen and King, 2007). Attenu-
ated angiogenic response to tissue injury and hypoxia in dia-
betes likely contribute to the strong propensity to develop
persistent decubitus and foot ulcers (Brem and Tomic-Canic,
2007; Falanga, 2005). The blunted angiogenesis may in part be
caused by vascular endothelial growth factor (VEGF) resistance,
in which there is reduced receptor signaling despite higher ligand
expression, akin to insulin resistance (Sasso et al., 2005; Simons,
2005). Other signaling pathways have been also proposed to
underlie diabetic endothelial dysfunction, including accelerated
formation of advanced glycation endproducts, activation of
protein kinase C, increased proinflammatory signaling, and
impaired sensitivity of the phosphatidylinositol-3 kinase/Akt
pathway (Potenza et al., 2009). However, the exact mechanisms
by which angiogenic response is impaired in diabetes remain
poorly understood.
PGC-1a is a transcriptional coactivator that regulates meta-
bolism in numerous tissues. PGC-1a belongs to a small family
of coactivators, comprised of PGC-1a, PGC-1b, and the more
distant PRC (Rowe et al., 2010). Although originally named for
its ability to coactivate PPARg, it is now clear that PGC-1a coac-
tivates a broad range of transcription factors, likely includingc.
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tions in different tissues. In hepatocytes, PGC-1a activates a
gluconeogenic program in response to glucagon and low levels
of insulin (Herzig et al., 2001; Yoon et al., 2001). In brown fat,
PGC-1a responds to cold exposure and drives thermogenesis
(Puigserver et al., 1998). In muscle and heart, PGC-1a powerfully
activates a broad program ofmitochondrial biogenesis (Lin et al.,
2002; Russell et al., 2004). PGC-1a thus regulates metabolic
programs in numerous cell types.
We have recently shown in muscle and heart that PGC-1a also
regulates the formation of blood vessels (Arany et al., 2008;
Patten et al., 2012), thus coordinating the control of fuel con-
sumption in mitochondria with fuel delivery via blood vessels.
PGC-1a regulates the expression of a number of angiogenic
factors, including the canonical VEGF. Activation of VEGF is
achieved by coactivation of ERRa, independently of hypoxia-
inducible factor (HIF) activity. Transgenic expression of PGC-
1a in myocytes dramatically increases capillary density in
skeletal muscle and provides protection in an ischemic model
(Arany et al., 2008). Conversely, deletion of PGC-1a in myocytes
blocks the normal ability of mice to increase vascular content in
response to exercise (Chinsomboon et al., 2009), and deletion of
PGC-1a in cardiomyocytes leads to profound vascular defects
and peripartum cardiomyopathy (Patten et al., 2012).
The above studies demonstrated that PGC-1a in myocytes
critically regulates angiogenesis. The key cells that carry out
angiogenesis, however, are the endothelial cells (ECs). The role
of PGC-1a in ECs, if any, is much less studied. PGC-1a may
have antiapoptotic properties in ECs (Won et al., 2010), as well
as anti-ROS and anti-inflammatory properties (Borniquel et al.,
2006; Kim et al., 2007; Valle et al., 2005). Studies of endothelial
PGC-1a in intact animals are lacking. No studies have investi-
gated a potential role of endothelial PGC-1a in diabetes. PGC-
1a in the skeletal myocyte has been proposed to contribute to
the etiology of insulin resistance (Mootha et al., 2003), although
this remains controversial. Persistent upregulation of PGC-1a
in the diabetic liver mediates hyperglycemia (Herzig et al.,
2001; Yoon et al., 2001). Although these findings suggest broad
implication of PGC-1a in diabetic pathophysiology, a role for
PGC-1a in mediating or protecting against diabetic complica-
tions in the vasculature, if any, has not been investigated.
We show here, using both cell culture and a number of endo-
thelial-specific genetic mouse models, that PGC-1a in ECs is
induced by diabetes, strongly inhibits endothelial migration and
angiogenesis in vivo, and mediates vascular dysfunction in
diabetes.
RESULTS
Diabetes Induces PGC-1a Expression in ECs
Diabetes is known to induce PGC-1a expression in the liver
(Herzig et al., 2001; Yoon et al., 2001). To test the effects of dia-
betes on PGC-1a expression in ECs in vivo, mice were fed a
high-fat diet (HFD) to induce type 2 diabetes and elevated
glucose concentrations (Figure S1A available online). PGC-1a
expression more than doubled in ECs isolated from either lung
or heart tissue of these diabetic mice, compared to control
animals (Figure 1A, left panels). PGC-1a was similarly induced
in ECs in two genetic models of type 2 diabetes (ob/ob andCell Mdb/db) and in streptozotocin-induced type 1 diabetes (Figure 1A,
right panels; Table S1). Human circulating CD34+ cells, which
contain significant numbers of endothelial progenitor cells
(EPCs) (Asahara et al., 1997; Fadini et al., 2006), isolated from
patients with type 2 diabetes (see Table S2) as well as cultured
EPCs established from the peripheral blood of diabetic patients
also revealed elevated expression levels of PGC-1a, compared
with control subjects (Figure 1B). Diabetes thus induces expres-
sion of PGC-1a in ECs in vivo in mice, and likely in humans
as well.
The observation that both type 1 and type 2 diabetes induce
PGC-1a expression in ECs suggested that hyperglycemia, rather
than insulin resistance, stimulates endothelial PGC-1a. To test
this, primary murine ECs were isolated from skeletal muscle,
using standard techniques with CD31 antibody-coated bead
cell capture. When these cells were cultured in high glucose
(25 mM) and subsequently placed in physiological glucose con-
centrations (5.5 mM), the expression of PGC-1a rapidly declined
by >90%within 4 hr (Figure 1C). This effect wasmimicked by the
addition of 2-deoxy glucose, an inhibitor of glycolysis (Figure 1D).
Conversely, addition of high glucose to cells grown in low
glucose induced PGC-1a mRNA expression (Figure 1E) and
protein (Figure S1B). Treatment with mannitol had no effect,
indicating that the induction of PGC-1a expression by high
glucose is independent of osmotic effects (Figure 1E). Inhibition
of reactive oxygen species (ROS) with N-acetyl cysteine (NAC)
blocked the induction of PGC-1a (Figure S1C), while inhibition
of O-GlcNAc transferase, the rate-limiting enzyme in glucose-
mediated glycosylation pathways, did not (Figure S1C), suggest-
ing that hyperglycemia-induced ROS production (Cosentino
et al., 2003) (Figure S1D) mediates the induction of PGC-1a.
Together, these data indicate that diabetes, likely at least in
part via hyperglycemia, induces PGC-1a expression in ECs
in vivo. Other pathways may also contribute.
PGC-1a Inhibits Endothelial Migration
Endothelial cell migration is a hallmark of endothelial function
(Carmeliet and Jain, 2011) and is blunted in diabetes (Chen
et al., 2007; Kra¨nkel et al., 2005; Yan et al., 2009). Consistent
with this, ECs isolated from streptozotocin (STZ)-treated ani-
mals, as well as from db/db animals, migrated significantly less
in Transwell migration assays than did cells from control animals
(Figures 2A, left panel, and 2B), as has been seen by others
(Bae et al., 2013; Cui et al., 2011; Yan et al., 2009). EPCs isolated
from diabetic patients revealed similarly blunted migration (Fig-
ure 2C). The blunting of migration coincided with induction of
PGC-1a expression (Figures 1B and 2A, right panels), suggest-
ing that PGC-1amay contribute to the decrease in cell migration.
To test this notion, ECswere isolated frommice that overexpress
PGC-1a specifically in ECs (see below for description of the
mice). PGC-1a in these cells was induced 6-fold to 7-fold
compared to cells from littermate controls (Figure 2D, right
panel), a level of induction that is comparable to that seen in
the STZ-treated wild-type animals (Figure 2A). ECs that overex-
pressed PGC-1a displayed significantly repressed migration, as
measured in Transwell migration assays (Figure 2D, left). To vali-
date this observation in cell-culture models, human umbilical
vein ECs (HUVECs), primary mouse muscle ECs (MMECs),
and primary human endothelial colony-forming cells (ECFCs)etabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Inc. 247
Figure 1. Diabetes Induces PGC-1a Expression in ECs
(A) Relative PGC-1a mRNA abundance in ECs freshly isolated from mouse models of type 1 (STZ) and type 2 (HFD, ob/ob, and db/db) diabetes. NC indicates
normal chow.
(B) Relative PGC-1a mRNA abundance in vasculogenic circulating CD34+ cells and cultured endothelial progenitor cells (EPCs) isolated from patients with
diabetes, versus matched normal subjects.
(C) Relative PGC-1a mRNA abundance in mouse muscle ECs (MMECs) at the indicated times after changing from hyperglycemia to normal glucose levels.
(D) Relative PGC-1a mRNA abundance in MMECs in absence or presence of 2-deoxyglucose (2DG) for 24 hr.
(E) Relative PGC-1a mRNA abundance in mouse heart ECs (MHECs) 2 and 4 hr after exposing cells to hyperglycemia or hyperosmolarity (mannitol). *p < 0.05.
n = 3–5. Data are means ±SEM. See also Figure S1 and Tables S1 and S2.
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expressing PGC-1a, versus control. Endothelial migration was
profoundly inhibited by expression of PGC-1a, as measured in
scratch assays (Figure 2E) or in Transwell migration assays (Fig-
ures 2F–2G, S2A, and S2B). Overexpression of PGC-1a also in-
hibited the formation of tube-like structures by ECs (Figure 2H)
while having little effect on cell viability (Figure S2C). Diverse
promigratory stimuli, including VEGF (Figures 2F and S2B) or
sphingosine 1-phosphate (S1P) (Figures 2G, S2A, and S2B),
were blocked by PGC-1a. Interestingly, time-lapse videoscopy
revealed that cells overexpressing PGC-1a remained capable
of small-distance random vibration but failed to undergo direc-
tional cell movement (Movies S1 and S2). Consistent with this,
the ability of VEGF and S1P to activate lamellipodia and stimu-
late assembly of subcortical F-actin was profoundly impaired
(Figure 2I), mimicking defects seen in ECs isolated from db/db
mice (Figure 2J), STZ-treated mice (Figure S2D), or diabetic
patients (Figure S2E).
VEGF and S1P act through distinct cell surface receptors
(receptor tyrosine kinase versus G protein-coupled receptor,
respectively) but converge on at least two intracellular signaling248 Cell Metabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Incascades: the ERK and Akt pathways. Endothelial cell cytoskel-
etal activation occurs in large part in response to Rac/Akt/eNOS
signaling (Levine et al., 2007; Sawada et al., 2008). To test which
signaling pathways are affected by PGC-1a, cells overexpress-
ing PGC-1a were stimulated with VEGF or S1P, and activation
of Akt, eNOS, and ERKwasmeasured by phospho-protein west-
ern blotting. Overexpression of PGC-1a had little impact on acti-
vation of the ERK pathway by either VEGF or S1P (Figures 2K
and 2L). By contrast, overexpression of PGC-1a strongly in-
hibited the activation of Akt (phosphorylation at Ser473) and
eNOS (phosphorylation at Ser1177) by both VEGF and S1P
(Figures 2K and 2L), as well as the production of NO (Figure S2F).
PGC-1a thus inhibits the Akt/eNOS proangiogenic pathway.
Interestingly, PGC-1a did not inhibit insulin-mediated Akt acti-
vation (Figure S2G), indicating that PGC-1a specifically sup-
presses only certain pathways.
PGC-1a Activates Notch Signaling to Inhibit Endothelial
Migration
Notch signaling is increasingly recognized as a powerful
inhibitor of endothelial migration and sprouting angiogenesisc.
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Williams et al., 2006). The Notch cell surface receptor is
sequentially cleaved by matrix metalloproteases and g-secre-
tase, leading to nuclear localization of the Notch intracellular
domain (NICD). NICD in turn induces the expression of key
target genes including Hes1, Hey1, Nrarp, and RBPj, while
repressing the expression of other genes, including Kdr
(VEGFR2). Overexpression of PGC-1a in ECs increased the
presence of the NICD (Figure 3A), and even mild induction of
PGC-1a in cell culture (Figure S3A) or in vivo (Figure 3B) in
ECs was sufficient to generate a gene expression signature
of Notch activation that mimicked that seen in ECs treated
with high glucose (Figure S3B) or harvested from STZ-treated
mice (Figure S3C), from db/db mice (Figuer S3D), or from dia-
betic patients (Figure S3E). PGC-1a thus activates Notch
signaling in ECs in culture and in vivo.
Treating PGC-1a-overexpressing ECs with DAPT, a g-secre-
tase inhibitor, rescued the PGC-1a-mediated inhibition of
migration (Figure 3C), indicating that the activation of Notch
by PGC-1a is in part necessary for the inhibition of endothelial
migration. Capillary sprouting from aortic explants, an ex vivo
model of angiogenesis, was next used to test the effect of
PGC-1a on capillary formation. Aortic explants were excised
from mice overexpressing PGC-1a in ECs, versus littermate
controls. Overexpression of PGC-1a strongly inhibited the for-
mation of capillary sprouts in this model (Figure 3D). As with
the inhibition of migration (Figure 3C), DAPT rescued the inhibi-
tion of capillary sprouting (Figure 3D). PGC-1a thus inhibits
endothelial migration at least in part via activation of Notch
signaling.
PGC-1a had no apparent impact on HIF-1a protein (Fig-
ure S3F) or on HIF-1a target genes (Figure S3G), echoing our
previous results in skeletal muscle cells (Arany et al., 2008).
PGC-1a also had only a mild effect on ROS-detoxifying enzymes
(Figure S3H) and on the presence of ROS (Figure S3I), suggest-
ing that the effect of PGC-1a on Notch likely involves other
mechanisms. Inhibition of Notch signaling with either DAPT or
GM6001, a pan-MMP inhibitor (Figure 3E), blocked the induction
of Notch target genes by PGC-1a, indicating that PGC-1a likely
acts upstream or at the level of the first Notch cleavage step by
MMP/ADAM-family proteases. We next identified ADAMTS10,
an ADAM-like MMP, as strongly induced in ECs from PGC-
1a-overexpressing animals, as well as in ECs treated with high
glucose and in ECs from diabetic animals or diabetic patients
(Figure 3F). Knockdown of ADAMTS10 (Figure 3G) blocked the
PGC-1a-mediated induction of Notch target genes (Figure 3H)
as well as the PGC-1a-mediated suppression of endothelial
migration (Figure 3I) (interestingly, migration is in fact increased
by shADAMTS10). PGC-1a thus likely activates Notch signaling
in part via the induction of ADAMTS10.
Loss of PGC-1a Activates EC Migration
The data above suggested that PGC-1a in ECs may act down-
stream of angiogenic stimuli. To test this, expression of PGC-
1a was monitored after the addition of proangiogenic agents.
As shown in Figure 4A, VEGF, S1P, and S-nitrosoglutathione
(GSNO, an NO donor) rapidly inhibited the expression of
PGC-1a in ECs—by as much as 90% within 4 hr. The suppres-
sion of PGC-1a expression was relieved by inhibition of PI-3KCell Mor Akt (Figure S4A). These data thus suggest that inhibition of
PGC-1a may be necessary for EC activation and migration. To
test directly the effects of loss of PGC-1a, ECs were isolated
from PGC-1a/ animals and littermate controls. The migratory
capacity of the cells was then evaluated, using scratch and
Transwell assays. In both cases, cells that lacked PGC-1a
were markedly hypermigratory, to an extent comparable to con-
trol cells stimulated by VEGF (Figures 4B and 4C). Deletion of
PGC-1a is therefore sufficient to mimic stimulation by VEGF.
Capillary sprouting was also increased in aortic explants from
PGC-1a/mice (Figure 4D), reflecting the key role of EC migra-
tion in capillary sprouting. The increased capillary-forming
propensity of PGC-1a/ vessels is reminiscent of the reported
phenotypes of those deficient in Notch signaling (Leslie et al.,
2007; Suchting et al., 2007). Indeed, the expression of Notch
target genes was depressed in PGC-1a/ cells (Figure 4E), mir-
roring the induction of the same genes in cells overexpressing
PGC-1a (Figure 3B). Phosphorylation of Akt and eNOS was
increased in PGC-1a/ cells (Figure S4B); activation of Rac1
was constitutive in PGC-1a/ ECs (Figure 4F), and inhibition
of Rac (with NSC23766) or eNOS (with L-NAME or DPI) reversed
the hypermigratory phenotype of PGC-1a/ cells (Figure 4G),
again indicating that PGC-1a inhibits the Rac/Akt/eNOS
pathway. VEGF-induced ROS formation was not altered in
PGC-1a/ cells (Figure S4C), again showing the minimal contri-
bution of ROS in mediating the antimigratory effect of PGC-1a.
Together with the gain-of-function data shown in Figure 2, these
data demonstrate that PGC-1a powerfully inhibits Rac/Akt/
eNOS signaling, and migration, in ECs.
Endothelial PGC-1a Inhibits Angiogenesis In Vivo
Endothelial cell migration is critical for the formation of new
blood vessels. To test if PGC-1a inhibits the formation of blood
vessels, we used an in vivo model of vasculogenesis in which
ECFCs and mesenchymal progenitor cells are coinjected into
nude mice (Yoder et al., 2007). Injection of ECFCs that overex-
press PGC-1a significantly blunted the formation of new blood
vessels in this model, compared to the use of control ECFCs
(Figure 5A). To further test the role of endothelial PGC-1a in vivo,
two double transgenic lines of mice with inducible expression of
PGC-1a in ECs were generated, using either tetracycline-
inhibited (‘‘Tet-off’’) or tetracycline-activated (‘‘Tet-on’’) versions
(Figure 5B). Importantly, PGC-1a expression in the Tet-on
mouse ECs in vivo was induced 5-fold to 7-fold (Figure 5C),
roughly equivalent to the induction of PGC-1a seenwith diabetes
(Figure 1). Expression of PGC-1a in transgenic mouse endo-
thelium did not affect baseline vascular density (Figure S5A) or
systemic glucose handling (Figures S5B and S5C; Table S1),
suggesting that endothelial PGC-1a does not play a prominent
role in the systemic regulation of glucose levels.
Endothelial cell migration is critical for re-endothelialization of
vessel walls after wire injury, as occurs during percutaneous
vascular interventions, and this process is dysfunctional in
diabetes (Aronson et al., 1996; Mohan et al., 2008). Transgenic
expression of PGC-1a in ECs strongly inhibited re-endo-
thelialization in a carotid injury model (Figures 5D, 5E, and
S5D). Endothelial cell migration and angiogenesis are also
critical for various steps of wound healing, a process that is
also dysfunctional in diabetes (Brem and Tomic-Canic, 2007;etabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Inc. 249
Figure 2. Endothelial PGC-1a Inhibits Cell Migration
(A) Reduced migration of mouse heart ECs (MHECs) that were affinity-purified from STZ-treated mice and cultured to passage 2 (left), coincident with increased
expression of PGC-1a mRNA (right).
(B and C) Reduced migration of mouse lung ECs (MLECs) isolated from db/db mice toward S1P (B) and cultured EPCs isolated from diabetic patients (C).
(D) Reduced migration (left) of MHECs isolated from mice that overexpress PGC-1a (right) in ECs.
(E–G) Stable expression of PGC-1a inhibits migration of HUVECs in scratch assays (E) and in Transwell assays stimulated by 10 ng/ml VEGF (F) or 100 nMS1P (G).
(H) Stable expression of PGC-1a inhibits the tube-forming activity of HUVECs.
(legend continued on next page)
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Figure 3. Endothelial PGC-1a Activates
Notch to Inhibit Cell Migration
(A) Expression of PGC-1a in HUVECs activates
Notch signaling, as assessed by western blotting
of the Notch intracellular domain (NICD).
(B) mRNA expression of known Notch target
genes in the endothelial compartment of the
skeletal muscle from EC-specific PGC-1a-over-
expressing mice, versus controls.
(C) Inhibition of Notch signaling with DAPT (2.5 mM)
rescues inhibition of migration in HUVECs retro-
virally transduced with PGC-1a.
(D) Inhibition of Notch signaling with DAPT (2.5 mM)
rescues inhibition of capillary formation in mouse
aortic explants from EC-specific PGC-1a-over-
expressing mice.
(E) DAPT (2.5 mM) and pan-MMP inhibitor
GM6001 (25 mM) equally inhibited the upregulation
of Notch downstream gene mRNA expression
in HUVECs retrovirally transduced with PGC-1a.
(F) Increased mRNA abundance of ADAMTS10
in the MHECs isolated from EC-specific PGC-1a
transgenic mice, the endothelial compartment of
STZ-induced diabetic mouse lung, cultured EPCs
from diabetic patients, and human dermal micro-
vascular ECs treated with high glucose for 24 hr.
(G) Gene knockdown efficiency by lentiviral
transduction of HUVECs with short hairpin RNA
targeting ADAMTS10.
(H and I) Knockdown of ADAMTS10 with shRNA
abrogates the mRNA expression signature of
Notch activation (H) and reduced Transwell
migration toward S1P (I) by retroviral over-
expression of PGC-1a in HUVECs. *p < 0.05
versus control. **p < 0.01. Data are means ±SEM.
Scale bar indicates 500 mm. n = 3–18 for all groups.
See also Figure S3.
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both Tet-on and Tet-off lines, strongly inhibited the rate of
wound healing in a dorsal skin punch injury model (Figures 5F,
5G, S5E, and S5F).
Normal EC function and NO production are also needed
for vascular reactivity to endothelium-dependent vasodilatory
agents such as acetylcholine. Impaired endothelial-dependent
vasodilatory response is a hallmark of diabetic endothelial(I–L) PGC-1a inhibits cortical F-actin (green) polymerization in response to VEGF and S1P (I), mimicking th
stimuli in db/dbmouse lung ECs (J), and blocks activation of Akt and eNOS (but not Erk) by VEGF and S1P ([K
[L]) in human ECFCs. Arrowheads in (I) and (J) denote lamellipodia. *p < 0.05; **p < 0.01; n = 3–8. Data aremean
See also Figure S2 and Movies S1 and S2.
Cell Metabolism 19, 246–258dysfunction (Rask-Madsen and King,
2007). Transgenic expression of PGC-
1a had no effect on baseline blood pres-
sure, systemic vascular resistance, or
blood flow across the carotid artery (Fig-
ures S5G and S5H), but the ability to
increase blood flow in response to
acetylcholine challenge was significantly
blunted (Figure S5H). Consistent with
this, explanted vessels from mice ex-pressing EC-PGC-1a revealed blunted vascular reactivity to
carbachol compared to littermate controls (Figure S5I).
Finally, transgenic expression of PGC-1a also strongly in-
hibited the rate of recovery of blood flow in a murine hindlimb
ischemia model of peripheral artery disease (Figures 5H and
5I), again a process that is dysfunctional in diabetes (Hazarika
et al., 2007; Simons, 2005; Yan et al., 2009). These data thus
demonstrate that expression of PGC-1a in ECs in vivo mimicse impaired F-actin (red) accumulation to the same
], with densitometric quantification at 0 and 5 min in
s ±SEM. Scale bars are 50 mm in (I) and 20 mm in (J).
, February 4, 2014 ª2014 Elsevier Inc. 251
Figure 4. Lack of PGC-1a Accelerates EC Migration and Decreases Notch Signaling
(A) Relative PGC-1a mRNA abundance in human dermal microvascular ECs stimulated with VEGF (10 ng/mL), S1P (100 nM), or S-nitrosoglutathione (GSNO,
100 mM).
(B and C) Isolated MHECs from PGC-1a/ (KO) mice are hypermigratory in scratch assays (B) and Transwell migration assays (C).
(D) Capillary formation of KO (n = 31) and wild-type (WT) (n = 16) mouse aortic explants.
(E) mRNA expression of known Notch target genes in ECs isolated from KO mice, versus wild-type controls.
(F) GTP-Rac1 pull-down assay in WT and KO MHECs.
(G) VEGF (10 ng/ml)-induced Transwell migration of KO andWTMHECs, with or without DPI (diphenyleneiodonium chloride, 10 mM), L-NAME (L-NG-Nitroarginine
Methyl Ester), or Rac inhibitor (NSC23766, 30 mM). *p < 0.05 versus control. **p < 0.01. The symbol # indicates p < 0.01 versus KO treated with vehicle. Data are
means ±SEM. n = 3–18 for all groups. See also Figure S4.
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independent of tetracycline, because both ‘‘Tet-on’’ and ‘‘Tet-
off’’ systems gave similar results. The effects are also almost
certainly a consequence of expression of PGC-1a expression
in the endothelium, because the effects are seen independently
with transgenes driven by the divergent VE-cadherin and Tie2
promoters.
Loss of Endothelial PGC-1a Rescues Diabetic
Endothelial Dysfunction
The above data suggested that vascular complications of dia-
betes are mediated, at least in part, via the induction of
PGC-1a in the endothelium. To test this directly, mice lacking252 Cell Metabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Inendothelial PGC-1a were generated via Cre/Lox recombination
(Figure S6A). The PGC-1a locus was deleted with >80% effi-
ciency, mRNA expression was repressed >70%, and PGC-1a
protein was undetectable in isolated ECs from these animals
(Figures S6B–S6D). The mice were then exposed to type 1 dia-
betes via STZ injection, or type 2 diabetes via high-fat feeding.
Deletion of endothelial PGC-1a did not reduce the hyperglyce-
mia seen with these models (EC-KO, 462.5 ± 55.2; control,
448.5 ± 42.7 mg/dl in type 1 diabetes model; see also Figures
S6E and S6F), again suggesting that endothelial PGC-1a does
not play a prominent role in the systemic regulation of glucose
levels. Blood pressure and serum lipid profiles were also unaf-
fected in EC-KO animals (Figure S6G; Table S1).c.
Figure 5. Induced Expression of Endothelial PGC-1a In Vivo Phenocopies Diabetic Vascular Dysfunction
(A) In vivo vasculogenesis assay using mesenchymal progenitor cells and human ECFCs expressing PGC-1a versus control vector. Left, sample appearance of
the Matrigel plugs. Middle, hematoxylin and eosin staining of plug sections. Right, quantification of vessel density.
(B) Schema of Tet-off and Tet-on tetracycline-inducible, endothelial-specific PGC-1a transgenic (Tg) mice.
(C) mRNA abundance of PGC-1a in freshly isolated lung ECs from transgenic animals versus control.
(D and E) Quantification (D) and representative images (E) of re-endothelialization following wire injury of mouse carotid arteries in Tet-off transgenic animals.
(F and G) Quantification (F) and representative images (G) of skin wound healing in Tet-off transgenic animals.
(H and I) Quantification of blood flow recovery (H) and necrotic toes (I) after induced hindlimb ischemia in Tet-on animals. n = 5–10 for all groups. *p < 0.05. Data are
means ±SEM. See also Figure S5.
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Figure 6. Ablation of Endothelial PGC-1a
Rescues Diabetic Mice from Defective
Wound Healing and Blood Flow Recovery
in Ischemic Limbs
(A) Skin wound healing in endothelial-specific
PGC-1a knockout (EC-KO) and control mice,
either nondiabetic or rendered diabetic by treat-
ment with STZ.
(B) Skin wound healing in EC-KO and control mice
that were fed HFD for 12 months.
(C–F) Recovery of blood flow after surgical in-
duction of hindlimb ischemia in type 1 diabetic
EC-KO animals: (C) representative day 14 laser
Doppler perfusion images, (D) quantification of
blood perfusion recovery in the ischemic limbs, (E)
number of necrotic toes in the ischemic foot at day
28, and (F) representative appearance of diabetic
mouse ischemic limbs at day 14.
(G and H) Recovery of blood flow after hindlimb
ischemia in type 2 diabetic EC-KO animals:
(G) quantification of blood perfusion recovery in
the ischemic limbs and (H) number of necrotic
toes in the ischemic foot at day 21. n = 6–14. *p <
0.05 versus EC-KO; the symbol x indicates
p < 0.05 versus control; the symbol { indicates
p < 0.05 versus EC-KO (diabetic). Data are
means ±SEM. See also Figure S6.
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type 1 diabetes (Seifter et al., 1981) and the high-fat fed model
of type 2 diabetes (Nascimento and Costa, 2006; Seitz et al.,
2010). As shown in Figures 6A and 6B, deletion of endothelial
PGC-1a significantly accelerated wound healing in both of
these diabetic models, rescuing the healing to nearly that
seen in nondiabetic animals. The recovery of blood flow in
murine hindlimbs after surgical induction of ischemia is also
severely retarded in diabetic mice and often leads to necrotic
limbs and autoamputation (Hazarika et al., 2007; Wang et al.,
2009; Yan et al., 2009) (Figures 6C, 6E, 6F, and 6H). Again,
deletion of PGC-1a in ECs reversed this defect in both type 1
and 2 diabetic models (Figures 6C–6H and S6H). Strikingly,
the necrosis and loss of limbs that is frequently seen in diabetic
animals after hindlimb ischemia was almost completely
reversed in mice lacking endothelial PGC-1a (Figures 6E, 6F,
and 6H). Deletion of PGC-1a in ECs also rescued the gene
signature of Notch activation in ECs that is seen after STZ treat-
ment (Figure S6I), indicating that PGC-1a is required for Notch
activation by diabetes, a process implicated in reduced VEGF
responsiveness of diabetic ECs (Cao et al., 2010). Together,
these data indicate that deletion of PGC-1a in ECs in large254 Cell Metabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Inc.part rescues numerous aspects of endo-
thelial dysfunction in diabetes.
DISCUSSION
Diabetes and hyperglycemia are associ-
ated with significant microvascular
dysfunction, leading to a large burden of
disease worldwide. The data presented
here indicate that PGC-1a is elevated inECs from diabetic organisms, that elevated endothelial PGC-
1a inhibits proper endothelial migration, and that deletion of
endothelial PGC-1a rescues multiple aspects of vascular
dysfunction in diabetes. We suggest that PGC-1a in ECs acts
as a brake on endothelial activation that is normally overcome
by stimulation with VEGF, S1P, and other angiogenic ligands.
Hyperglycemia induces PGC-1a in ECs and accentuates the
brakes on the system to a point that can no longer be overcome
by angiogenic stimuli. As a result, PGC-1a inhibits vessel re-en-
dothelialization, blunts wound healing, and worsens foot necro-
sis, all of which are characteristic features of diabetic vascular
complications. Conversely, deletion of PGC-1a in ECs rescues
these defects in diabetic models. These data thus indicate that
PGC-1a mediates in part the vascular dysfunction caused by
diabetes.
The data presented here identify PGC-1a as a potent negative
regulator of endothelial migration, likely affecting both angiogen-
esis and vasculogenesis, and functioning at least in part via in-
duction of Notch signaling. Notch signaling plays a central role
in maintaining ECs in a relatively nonactivated, stalk-like pheno-
type during sprouting angiogenesis (Leslie et al., 2007; Roca and
Adams, 2007; Suchting et al., 2007). The activation of Notch by
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in ECs, resistant to migration or angiogenesis. Indeed, Notch
inhibition has been shown to rescue VEGF resistance in diabetic
ECs and to improve blood flow recovery in the murine hindlimb
ischemia model (Cao et al., 2010). Activation of Notch by hyper-
glycemia and diabetes has also been described in renal podo-
cytes (Ahn and Susztak, 2010; Lin et al., 2010; Niranjan et al.,
2008) and in hepatocytes (Pajvani et al., 2011). The mechanism
by which Notch is activated by hyperglycemia is not known,
although interestingly, O-glucosylation of the extracellular
domain of Notch is required for Notch activity (Acar et al.,
2008; Rana and Haltiwanger, 2011). The data shown here indi-
cate that PGC-1a is required for Notch activation in diabetic
ECs. It will be of future interest to deconvolute how PGC-1a
induces Notch activity and inhibits Akt/eNOS. It will also be of
interest to investigate if a hyperglycemia/PGC-1a/Notch axis is
also at play in kidney and liver cells.
The data here also reveal an important relationship between
angiogenesis and a central regulator of metabolism. Metabolic
regulation of ECs is increasingly garnering interest, especially
in the context of cancer (Harjes et al., 2012). It will thus be of
interest to understand the role of PGC-1a in modulating EC
metabolism and understanding the role of metabolic perturba-
tions, if any, in EC and Notch activation. Cellular replication
and anabolism, such as occurs during angiogenesis, is generally
thought to require an increase in glycolytic flux at the expense
of fuel consumption in mitochondria. PGC-1a may inhibit this
process and thus may contribute to EC quiescence in this
manner as well.
Interestingly, baseline vascular density and development did
not appear to be affected by either deletion or overexpression
of endothelial PGC-1a in our mouse models. This suggests
that PGC-1a primarily mediates postnatal physiological and
pathological responses but has little role during development.
This is consistent with observations in other tissues: absence
of PGC-1a often has little effect at baseline but blunts responses
to physiological stimuli (Arany et al., 2005; Chinsomboon et al.,
2009; Lin et al., 2004).
Physiological endothelial activation is blunted in diabetes, but
pathological endothelial activation contributes to multiple pa-
thologies, including tumor angiogenesis and choroidal neovas-
cularization in age-related macular degeneration. It will therefore
be of interest to test if activation of endothelial PGC-1a can
inhibit these processes. Similarly, endothelial activation and
angiogenesis have also been proposed to contribute to athero-
sclerosis, although this remains controversial (Moulton et al.,
2003). PGC-1a/ mice are hyperactive and protected from
diet-induced obesity and diabetes (Lin et al., 2004), both of
which would be predicted to be antiatherosclerotic. Despite
this fact, total-body deletion of PGC-1a had a net-neutral effect
on atheromatous burden in ApoE/ mice (Stein et al., 2010).
Deletion of PGC-1a must thus also have proatherosclerotic
effects, which may stem from deletion of PGC-1a in the endo-
thelial compartment. It will therefore be of interest to test if
endothelial PGC-1a modulates atherosclerosis.
In summary, the work presented here supports the notion that
induction of PGC-1a in ECs mediates endothelial dysfunction
and vascular complications in diabetes. The data thus in princi-
ple identify endothelial PGC-1a as a potential new therapeuticCell Mtarget. We have shown previously, however, that in cardiomyo-
cytes and in skeletal myotubes, PGC-1a is proangiogenic by
virtue of stimulating the secretion of numerous proangiogenic
factors (Arany et al., 2008; Patten et al., 2012). Modulation of
PGC-1a in different cells would thus have opposing effects.
Similarly, activation of PGC-1a has been suggested as a thera-
peutic approach to improve insulin resistance, but the current
findings suggest that this might be achieved at the expense of
worsening diabetic complications. This striking observation
stresses the need for caution in therapeutic endeavors aimed
at PGC-1a in this and other contexts.EXPERIMENTAL PROCEDURES
Mouse and Human ECs
All procedures were performed using protocols approved at the relevant
institution by Institutional Review Boards for human studies and Institutional
Animal Care and Use Committees. Mouse ECs were isolated as described
(Sawada et al., 2008, 2009). Isolated ECs were either immediately harvested
to represent the endothelial compartment of mouse organs or cultured to
passage 2 or 3 for cell migration and other assays. Human umbilical vein
(HUVECs) and dermal microvascular ECs (HDMVECs) were purchased from
Lonza. The preparation of CD34+ cells was modified from our previous reports
for the preparation of CD133+ cells (Masuda et al., 2007, 2011; Nakamura
et al., 2012). Human ECFCs were isolated as previously described (Melero-
Martin et al., 2008).
Mouse Models
PGC-1a knockout mice are described (Lin et al., 2004). PGC-1a conditional
allele knockin mice (Handschin et al., 2007) were backcrossed at least eight
times onto the C57BL/6 strain. Two strains of Tie2-Cre transgenic mice were
used for the study. The first line (Flavell) (Koni et al., 2001) was obtained
from Jackson Laboratory (Bar Harbor). The second line (Yanagisawa) (Kisanuki
et al., 2001) was obtained from Dr. Thomas N. Sato. Two independent lines of
tetracycline-inducible, endothelial-specific PGC-1a transgenic mice were
generated. The first line (‘‘Tet-off’’ mice) was created as double Tg mice by
crossing VE-cadherin promoter-driven tetracycline transactivator (tTA) Tg
mice (VECad-tTA) (Sun et al., 2005) with tetracycline response element-driven
PGC-1a Tg mice (TRE-PGC-Ia) (Russell et al., 2004), a generous gift from Dr.
Dan Kelly. The second line (‘‘Tet-on’’ mice) was similarly generated by crossing
Tie2-promoter/enhancer-driven reverse tetracycline transactivator (rtTA) Tg
mice (Tie2-rtTA) (Teng et al., 2002), purchased from the Jackson Laboratory,
with TRE-PGC-1a mice. We used four diabetic mouse models: (i) STZ admin-
istration, (ii) high-fat feeding (HFD) using Rodent Diet with 60 kcal% fat (cat#
D12492, Research Diets Inc., New Brunswick), (iii) ob/ob mice (Charles River,
Yokohama), and (iv) db/dbmice (CLEA Japan, Tokyo). Endothelial denudation
of the common carotid artery was performed with five passes of an 0.14 in
guide wire, which was inserted through an arteriotomy in external carotid
artery. Carotid artery blood flow was recorded using an ultrasonic flow probe
placed on the artery and sampled at 0.1 kHz using a transit-time perivascular
flow meter (Transonic, MA0.5PSB and TS420, respectively). Wound healing
assay in vivo was performed according to a published method (Dioufa et al.,
2010). Hindlimb ischemia was performed as described previously (Sawada
et al., 2008).
Reagents and Cellular Assays
Anti-PGC-1a (H300) antibody was from Santa Cruz. Lentivirus gene knock-
down constructs were from RNAi Consortium (Broad Institute, Cambridge).
Tube formation assays (Jiang et al., 2009) and capillary sprouting assays
(Sawada et al., 2008, 2009) were performed as described previously. The intra-
cellular ROS levels of cells were determined using CM-H2DCFDA (Molecular
Probe). NO measurements were performed with 10 mM diaminofluorescein-2
(DAF-2) (Cayman Chemical, Ann Arbor), an NO-sensitive fluorescent dye.
Vascular reactivity of carotid artery explants to carbachol was performed as
described (Kanda et al., 2009).etabolism 19, 246–258, February 4, 2014 ª2014 Elsevier Inc. 255
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All data are expressed as means ±SEM. One-way or two-way ANOVA,
followed by post hoc Fisher’s test, was used for comparison between groups.
Values of p of <0.05 were considered significant. See Supplemental Experi-
mental Procedures for full description of the materials and methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, two movies, and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.cmet.2013.12.014.
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